Company Statements
04/10/2020
Gilead Sciences Response to Médecins Sans Frontières
03/25/2020
Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation
03/23/2020
Gilead Sciences Statement on Ensuring Continued Supply of HIV Medicine Amid Coronavirus Outbreak
03/22/2020
Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials
02/05/2020
01/31/2020
12/03/2019
11/07/2019
Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents
08/21/2019
Petitions to US Patent and Trademark Office on HIV PrEP Patents
06/11/2019
05/14/2019
Gilead Sciences Statement On Inaccurate Reporting On Truvada®
04/10/2019
Gilead Sciences Statement on Commitment to Providing Price Information
04/04/2019
Gilead Sciences Commits to Reducing our Global Greenhouse Gas Emissions by 25 Percent by 2025
04/03/2019
09/27/2018
09/24/2018
A perspective from our CEO: Gilead Subsidiary to Launch Authorized Generics to Treat HCV
09/07/2018
05/02/2018
Gilead Publishes 2017 Year in Review
11/09/2017
Gilead Sciences Announces 100 Percent Score on 2018 Human Rights Campaign Corporate Equality Index
09/01/2017
Gilead Implements Emergency Disaster Response Procedures to Ensure Medicine Access
05/01/2017
Gilead Publishes Year in Review 2016
12/06/2016
Gilead Recognized as Top Corporate Philanthropist in Funders Concerned About AIDS Report
12/01/2016
Gilead HIV Medicines Now Reaching 10 Million People in Developing Countries
11/11/2016
Statement on DISCOVER Study of F/TAF for PrEP
08/01/2016
Gilead Publishes 2015 Corporate Social Responsibility Report
08/14/2015
Gilead Supports PrEP Education to Increase HIV Prevention and Awareness
08/12/2015
Some of the content on this page is not intended for users outside